Existence of antimalarial formulations with low bioavailability in Tanzania

Tropical Doctor

Volumn 36, Issue 2, 2006, Pages 93-97

  Minzi, Omary M S ^a   Massele, Amosy ^a   Justin Temu, Mary ^b   Ericsson, Örjan ^c   Gustafsson, Lars L ^c  

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b School of Pharmacy   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; FANSIDAR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MARKETING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SAMPLING; SINGLE DRUG DOSE; TABLET FORMULATION; TANZANIA;

ADULT; ANTIMALARIALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUGS, GENERIC; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PYRIMETHAMINE; QUALITY CONTROL; SINGLE-BLIND METHOD; SULFADOXINE; TANZANIA; THERAPEUTIC EQUIVALENCY;

EID: 33645869557     PISSN: 00494755     EISSN: None     Source Type: Journal    
DOI: 10.1258/004947506776593512     Document Type: Article

References (25)

1. Massele AY, Sayi JG, Nsimba SED, Ofori-Adjei D, Laing RO. Knowledge and management of malaria in Dar es Salaam Tanzania. East Afr Med J 1993;70:639–642
2. Goodman C, Kachur SP, Abdulla S, et al. Retail supply of malaria-related drugs in rural Tanzania: risks and opportunities. Trop Med Int Health 2004;9:655–663
3. Weidekamm E, Rusing G, Caplain H, Sorgel F, Crevoisier C. Lack of bioequivalence of generic mefloquine tablet with the standard product. Eur J Clin Pharmacol 1998;54:615–619
4. Na-Bangchang K, Karbwang K, Palacios PAC, Ubalee R, Saengtertsilapachai S, Wernsdorfer WH. Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria. Eur J Clin Pharmacol 2000;55: 743–748
5. Jungheinrich C, Scharpf R, Wargenau M, Dilger C, Bepperling F. Pharmacokinetics of generic formulation Profol 1% Fresenius in comparison with the original formulation (Disoprivan® 1%). Clin Drug Invest 2002;22:417–427
6. Kayumba PC, Risha PG, Shewiyo D, et al. The quality of essential antimicrobial and antimalarial drugs marketed in Rwanda and Tanzania: influence of tropical storage conditions on in vitro dissolution. J Clin Pharm Ther 2004;29:331–338
7. Risha PR, Vervaet C, Vergote G, Van Bortel L, Remon JP. Drug formulations intended for global market should be tested for stability under tropical climatic conditions. Eur J Clin Pharmacol 2003;59:135–141
8. Stenson B, Lindgren BH, Synhakhang L, Tomson G. The quality of drugs in private pharmacies in the Lao People's Democratic Republic. Int J Risk Saf Med 1998; 11:243–249
9. Taylor RB, Shakoor O, Behrens RH, et al. Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 2001;357:1933–1936
10. Kun JF, Lehman LG, Lell B, Schmidt-Ott R, Kremsner PG. Low-dose treatment with sulfadoxine-pyrimethamine combinations selects for drug resistant Plasmodium falciparum strains. Antimicrob Agents Chemother 1999;43:2205–2208
11. Petralanda I. Quality of antimalarial drugs and resistance to plasmodium vivax in Amazonian region. Lancet 1995;345:1433
12. Minzi OMS, Moshi MJ, Hipolite D, et al. Evaluation of the quality of amodiaquine and sulfadoxine/pyrimethamine brands in private wholesale pharmacies in Dar es Salaam Tanzania. J Clin Pharm Ther 2003;28:117–122
13. Bergqvist Y, Hjelm E, Rombo L. Sulfadoxine assay using capillary blood dried on filter paper-suitable for monitoring of blood concentrations in the field. Ther Drug Monit 1987;9:203–207
14. Lilja JJ, Kivisto KT, Neuvonen PJ. Duration of effect of grapefruit Juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther 2000;68: 384–390
15. Winstanley PA, Watkins WM, Newton CRJC, et al. The disposition of oral and intramuscular pyrimethamine/sulfadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria. Br J Clin Pharmacol 1992;33:143–148
16. Minzi OMS, Massele AY, Ericsson Ö, Gustafsson LL. Simple and cost-effective liquid chromatographic method for determination of pyrimethamine in whole blood samples dried on filter paper. J chromatogr B 2005;814:179–183
17. Thomas NT, Rowland M. Clinical Pharmacokinetics. Concepts and Applications. 3rd edn. Philadelphia Lead Febiger, 1995: 367–389
18. Notari Robert E. Biopharmaceutics and Clinical Pharmaco-kinetics. An Introduction. 3rd edn. New York: Marcell Dekker, 1980:18–181
19. Food and Drug Administration. FDA Guidance Statistical Procedures for Bioequivalence Studies Using Standard Two-treatment Crossover Design. Washington, DC: FDA, 1992
20. Aubouy A, Bakary M, Keundjian A, Mbomat B. Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. Antimicrob Agents Chemother 2003;47:231–237
21. Risha PR, Shewiyo D, Msami A, et al. In vitro evaluation of essential drugs on the Tanzanian market. Trop Med Int Health 2002;7:701–707
22. Rimoy GR, Moshi MJ, Massele AY. Comparative bioavail-ability of oral sugar-coated and plain formulation of chloroquine phosphate marketed in Tanzania. Trop Doctor 1999;32:15–17
23. Ogwal-Okeng JW, Okello DO, Odyek O. Quality of oral and parenteral chloroquine in Kampala. East Afr Med J 1998;75:692–694
24. Mahamood BM, Ali HM, Homeida MMA, Bennet JL. Bioequivalence of five chloroquine brands marketed in Sudan. Pharm J 1994;8:164–167
25. Maponga C, Ondari C. The Quality of Antimalarials: A Study in Selected African Countries. WHO 2003,WHO/ EDN/PAR/2003.4. Geneva